The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10 ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. Read more about PFE stock here.

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...

Fall is upon us. In other words, it’s virus time. Kids are back in school – a great petri dish for cooking up viruses to take ...

Jay Timmons, President & CEO of the National Association of Manufacturers, warns that a strike could hurt manufacturers like ...

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...

Reverse flips’ are being triggered by the desire of firms to tap into India’s deepening capital market which is in the midst ...

Doctors are warning a messaging void about Alberta's fall immunization campaign could lead to more COVID-19 and flu ...

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...